Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
Curr Hematol Malig Rep
.
2009 Oct;4(4):185-6.
doi: 10.1007/s11899-009-0034-1.
Authors
Nicole Lamanna
1
,
Mark A Weiss
Affiliation
1
Leukemia Service at Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
PMID:
20425406
DOI:
10.1007/s11899-009-0034-1
No abstract available